The Intellectual Property (Miscellaneous Provisions) Bill 2014, which is published today, will enhance the immunity from patent infringement for companies involved in testing generic versions of drugs while the original drugs continue to enjoy patent protection. A case in 1984 in the United States resulted in legislation allowing for the Bolar Exemption, which allows companies to use patent-protected drugs in tests to develop […]
